Member Directory

Below all members are listed in alphabetical order. Click the tabs above to view working group members.

Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Nicole Ammerman is a Research Associate in the Department of Medicine, Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. She has a PhD in Microbiology and Immunology from the University of Maryland School of Medicine and an ScM in Epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her research focuses on the experimental chemotherapy of tuberculosis and nontuberculous mycobacterial diseases.

Terrence F. Blaschke, MD, is Professor of Medicine and Molecular Pharmacology (Emeritus) at Stanford University.

Conflict of Interest: Dr. Blaschke has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Durect Corporation, Cupertino California

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine.

Conflict of Interest: I am a member of a Data Monitoring Committee for Merck & Co.

Richard E. Chaisson, MD, is Professor of Medicine, Epidemiology, and International Health at Johns Hopkins University and Director of the Johns Hopkins Center for TB Research and the Center for AIDS Research.

Conflict of Interest: My spouse owns stock in Merck.  I have consulted for Sanofi.

Conflict of Interest: No disclosures.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie, where his areas of responsibility include viral diseases and cystic fibrosis. Dr. Cohen has extensive experience in clinical drug development for HIV and hepatitis C, and has been involved in the approval of Viekira Pak, Technivie, and Mavyret. 

Tine has a PhD in Veterinary Sciences from the University of Ghent, Belgium and earned her MBA in Pharmaceutical Management from Drexel LeBow College of Business. She has additional Masters degrees in Biology and Teaching. Tine is Compound Development Team Lead for Tuberculosis at Johnson & Johnson Global Public Health.

Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. 

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP).

Conflict of Interest: Dr. Flexner has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Algernon Pharmaceuticals; Gilead; Merck; Mylan Pharmaceuticals; ViiV Healthcare. 

Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. She previously worked at the Institut Pasteur, where she managed a 22-countries One Health Network of national laboratories, academia and public health institutions. Her previous work includes infectious diseases-related research and capacity building in low- and middle-income countries. 

Daria Hazuda, PhD, trained as a biochemist at the State University of New York at Stony Brook, N.Y. After completing her postdoctoral research fellowship in the department of Immunology at Smith Kline, she joined the antiviral research group as a Senior Research Biochemist at Merck in 1989.

Magali Hickey is the Director of Formulation Development at Alkermes Inc., a global biotechnology organization with a research and development facility located in Waltham, MA. Magali has over 10 years of experience in the pharmaceutical industry with interests focused on development of small molecules into viable drug products.

Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. 

Conflict of Interest: No disclosures.

Jeffrey M. Jacobson, MD is Professor of Medicine at Case Western Reserve University and Principal Investigator of the Case AIDS Clinical Trials Unit. 

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Dr. Johnson’s research interests include the design and development of polymer-based biosensors and drug delivery systems and translation to early stage products. She currently leads a research group focused on the development long-acting biodegradable implants for prevention and treatment of HIV and as a multipurpose prevention technology

Andy Kaytes has been an active member and currently co-chairs the Community Advisory Board at the University of California San Diego’s Antiviral Research Center since 2004.

Conflict of Interest: Andy has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Bristol Myers Squibb

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. 

Mila Maistat works as Policy and Advocacy Manager with the Medicines Patent Pool (MPP). She has almost 20 years of experience of working in public health, in particular, viral hepatitis and HIV policy, advocacy and access to medicines. Mila has been serving with WHO as a member of WHO STAC on viral hepatitis and the WHO guidelines’ development and peer-review groups, development of regional and country plans on HIV, viral hepatitis and TB, used to chair HepC Group for the UNITAID NGO delegation, member of HIV, viral hepatitis and TB in Europe Steering Committee, part of organizing and scientific committees for international conferences and meetings on viral hepatitis and HIV.

Craig McClure leads the Viral Hepatitis Program at the Clinton Health Access Initiative (CHAI). In this capacity, he directs a global team supporting seven countries in Africa and Asia to scale up diagnosis and treatment of viral hepatitis, with an emphasis on hepatitis C, including market-shaping interventions to introduce innovations in diagnostics and drugs, increase volumes and drive down pricing, support for policy and program development, financing, training of health workers, and monitoring and evaluation.

Ms. McKenzie-White is Managing Director and Senior Program Officer at the Center for Clinical Global Health Education.

Conflict of Interest: I have no real or apparent conflicts of interest to report.

Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center.

Conflict of Interest: Dr. Mirochnick has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck, ViiV, Gilead, ReViral.

Dr. Nuermberger is an Associate Professor of Medicine and International Health at Johns Hopkins University. His primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials.

David has >20 years of infectious disease drug discovery experience with a focus on HIV-1 and HCV. In 2011 he was given the responsibility of directing Merck’s Neglected Tropical Disease discovery efforts that includes tuberculosis, macrofilaria, Chagas, Leishmania, malaria and Ebola.

Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. 

Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare

Dr. Chuck Peloquin received his BS in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. 

Manuele Piccolis joined the Medicine Patent Pool as Scientific Manager for Infectious Diseases in March 2020. He holds a PhD in Life Sciences from the University of Geneva and he has an extensive experience in metabolism. Before joining MPP Manuele worked extensively on lipid metabolism at the Gladstone Institutes (CA), Harvard HSPH (MA) and the EPFL (CH).

Dr. Podany is currently an Assistant Professor in the department of pharmacy practice at the University of Nebraska Medical Center.

Dr. Rangaka is an Associate Professor within the Institute of Global Health, University College London (UCL), United Kingdom. She is also affiliated to the MRC Clinical Trials Unit at UCL and is an honorary Associate Professor at the University of Cape Town (UCT), South Africa.

Bart Remmerie, Chem. Eng., graduated as a bio-engineer and as environmental engineer at Ghent University, Belgium. He started at Janssen (Bioanalysis) in 1994 and joined the Clinical Pharmacology group in 2006, initially primarily working on neuroscience projects, and more recently also on anti-infectives. 

Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. From 2004 to 2006, he was also Vice President of Drug Safety and Public Health. Dr. Rooney has been instrumental in the clinical development of the company's antiviral therapies, including treatments for HIV, hepatitis B and influenza.

Kimberly Scarsi is an Associate Professor at the University of Nebraska Medical Center’s (UNMC) College of Pharmacy. Her research program focuses on optimizing pharmacologic therapies for persons living with HIV, with an emphasis on global health and sex/gender related issues.

Dr Marco Siccardi graduated with an MSc in Clinical Biology (2006) at the University of Turin, Italy. He obtained his PhD at the University of Liverpool, Liverpool, UK (2011) focusing his research on molecular mechanisms influencing drug distribution and predictors of exposure in patients. He was recently appointed as a Lecturer in Pharmacology across the faculties of Health & Life Sciences and Science & Engineering at the University of Liverpool. 

Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Currently, he is Medicine Development Leader for the HIV integrase inhibitor cabotegravir, a long-acting injectable agent under investigation for both HIV prevention and treatment.

Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. 

Conflict of Interest: None disclosed.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Associate Dean for Research in the Capital Region (CAPRES). 

Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA.

Conflict of Interest: Dr. Swindells reports research grants to her institution from ViiV Healthcare.

Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a Masters in Public Health at the University of California at Berkeley. 

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine.

Conflict of Interest: I have no real or apparent conflicts of interest to report.